In the cohort of 58 selected patients with myeloid neoplasms (see Table 1, 2, and Additional File 1: Table S1 for patient characteristics), the EZH2 gene showed mutations (mostly missense or nonsense) in 6/51 AML patients (12%) and 7/7 non-AML patients (selected specifically for this genotype, hence 100%, Table 2), and was unmutated in 45/51 AML patients (88%). This evidence concerns the gene EZH2 and myeloid neoplasm.